VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
LFMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
LFMDLifeMD, Inc.
$4.87$236M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

LFMD logoLifeMD, Inc.(LFMD)Earnings, Financials & Key Ratios

LFMD•NASDAQ
$4.54
Price updated Jul 2, 2026
SectorHealthcareIndustryPharmaceuticalsSub-IndustryDigital Health and Online Pharmacy
AboutLifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.Show more
  • Revenue$194M-8.7%
  • EBITDA-$361K+94.6%
  • Net Income-$7M+62.4%
  • EPS (Diluted)-0.23+56.6%
  • Gross Margin79.75%-10.1%
  • EBITDA Margin-0.19%+94.1%
  • Operating Margin-3.95%+48.0%
  • Net Margin-3.66%+58.8%
  • ROE-74.37%+97.0%

LFMD Price & Volume

LifeMD, Inc. (LFMD) stock price & volume — 10-year historical chart

Loading chart...

Revenue Contraction Challenges Scalable Digital Margin Profile

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Mixed
Cash Flow:Mixed
Primary Risk:High Customer Acquisition Costs

Key Thesis Takeaways

  • LifeMD faces a critical inflection point as top-line revenue has contracted by 23.6% year-over-year in 2026Q1, signaling potential saturation or inefficiency in its marketing-driven customer acquisition model.
  • While the company has successfully reduced total debt from $25.1 million in 2025Q1 to $6.2 million in 2026Q1, the inability to maintain positive operating income—evidenced by a $8.9 million loss in 2026Q1—suggests that the business model struggles to achieve sustainable operating leverage.
  • Investors should monitor whether the company can stabilize its revenue base and improve cash conversion, as the current reliance on stock-based compensation and dividend payments amidst net losses warrants significant caution.

Verdict Logic

the company's inability to generate consistent profitability, highlighted by a -19.2% net margin in 2026Q1, suggests that the current business model remains fundamentally reliant on unsustainable capital allocation and marketing spend.

LFMD Growth Metrics

LifeMD, Inc. (LFMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years66.03%
5 Years39.08%
3 Years17.69%
TTM-6.18%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-66.04%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-30.12%

Return on Capital

10 Years-346.01%
5 Years-220.68%
3 Years-96.13%
Last Year-37.37%

LFMD Recent Earnings

LifeMD, Inc. (LFMD) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 6, 2026
Metric
Actual
Est
EPS
$0.20-42.9%
$0.14
Rev
$50M+2.7%
$49M
Q2 2026
Mar 9, 2026
Metric
Actual
Est
EPS
$0.04-300.0%
$0.01
Rev
$47M+2.3%
$46M
Q4 2025
Nov 17, 2025
Metric
Actual
Est
EPS
$0.10-66.7%
$0.06
Rev
$60M+23.9%
$49M
Q3 2025
Aug 5, 2025
Metric
Actual
Est
EPS
$0.05-126.0%
$0.18
Rev
$62M-6.2%
$66M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 6, 2026
$0.20vs $0.14-42.9%
$50Mvs $49M+2.7%
Q2 2026Mar 9, 2026
$0.04vs $0.01-300.0%
$47Mvs $46M+2.3%
Q4 2025Nov 17, 2025
$0.10vs $0.06-66.7%
$60Mvs $49M+23.9%
Q3 2025Aug 5, 2025
$0.05vs $0.18-126.0%
$62Mvs $66M-6.2%
Based on last 12 quarters of dataView full earnings history →

Latest LFMD News

Recent stock market news and headlines for LifeMD, Inc. (LFMD)

GlobeNewsWire·Jun 23, 2026
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on July 15, 2026, to holders of record at the close of business on July 3, 2026.

GlobeNewsWire·Jun 22, 2026
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing arrangement with LifeMD for the XYOSTED self-pay program, launching in July 2026 in 37 states

Peers Comparison

Key metrics vs top competitors for LifeMD, Inc. (LFMD)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
LFMD logoLFMDLifeMD, Inc.Current
$4.54$219.57M-19.74-8.66%-3.66%-74.37%1.52%
HIMS logoHIMSHims & Hers Health, Inc.
$37.57$8.25B73.6759%-0.56%-2.48%—
NUVB logoNUVBNuvation Bio Inc.
$5.42$1.88B-9.03698.96%-102.06%-44.1%—
DOCS logoDOCSDoximity, Inc.
$21.59$4.04B22.0313.05%30.4%19.36%—
OPRX logoOPRXOptimizeRx Corporation
$6.08$114.09M22.5218.78%6.37%5.47%—
TDOC logoTDOCTeladoc Health, Inc.
$9.10$1.64B-7.98-1.54%-6.81%-12.37%—

Compare LFMD vs Peers

LifeMD, Inc. (LFMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HIMS

Most directly comparable listed peer for LFMD.

Scale Benchmark

vs AMZN

Larger-name benchmark to compare LFMD against a more recognizable public peer.

Peer Set

Compare Top 5

vs HIMS, NUVB, DOCS, OPRX

LFMD SEC Filings & Documents

LifeMD, Inc. (LFMD) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 6, 2026·SEC

Material company update

Mar 18, 2026·SEC

Material company update

Mar 9, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 10, 2026·SEC

FY 2025

Mar 11, 2025·SEC

FY 2024

Mar 11, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 6, 2026·SEC

FY 2025

Nov 17, 2025·SEC

FY 2025

Aug 5, 2025·SEC

Get notified when LFMD posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

LFMD Frequently Asked Questions

LifeMD, Inc. (LFMD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is LifeMD, Inc.'s revenue?

LifeMD, Inc. (LFMD) reported $219.4M in revenue for fiscal year 2025. This represents a 29399% increase from $0.7M in 2011.

How fast is LifeMD, Inc. growing?

LifeMD, Inc. (LFMD) saw revenue decline by 8.7% over the past year.

Is LFMD profitable?

LifeMD, Inc. (LFMD) reported a net loss of $17.0M for fiscal year 2025.

Dividend & Returns
Does LFMD pay dividends?

Yes, LifeMD, Inc. (LFMD) pays a dividend with a yield of 1.52%. This makes it attractive for income-focused investors.

What is LFMD's return on equity?

LifeMD, Inc. (LFMD) has a return on equity (ROE) of -74.4%. Negative ROE indicates the company is unprofitable.

What is LifeMD, Inc.'s free cash flow?

LifeMD, Inc. (LFMD) generated $14.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in LFMD back in 2011?

Total return calculator · dividends reinvested · 15+ years of data

See returns →